Sponsor

Transgene

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Transgene appears in 8 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials8
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

8 shown
A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)NCT05788926 · lead sponsor · 2023-04-05
TERMINATED
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid TumorsNCT04725331 · lead sponsor · 2021-02-25
TERMINATED
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)NCT03353675 · lead sponsor · 2018-01-05
COMPLETED
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung CancerNCT01383148 · lead sponsor · 2012-04-01
TERMINATED
Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung CancerNCT00415818 · lead sponsor · 2005-12-01
COMPLETED
Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate CancerNCT00040170 · lead sponsor · 2002-05-01
TERMINATED
TG4010 and Nivolumab in Patients With Lung CancerNCT02823990 · collaborator · 2016-12-14
COMPLETED
A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)NCT02630368 · collaborator · 2015-09-18
UNKNOWN

Sponsor roles

lead sponsor6
collaborator2
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.